{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.3","value":"127"},{"groupId":"OG001","spread":"35.6","value":"160"},{"groupId":"OG002","spread":"7.00","value":"165"},{"groupId":"OG003","spread":"20.1","value":"149"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Serum samples were collected from the participants at the defined timepoints. AUC (0-14) was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who weighed \\>= 35 kg were administered durvalumab 20 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\>= 35 kg were administered durvalumab 30 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG001","title":"Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\< 35 kg were administered durvalumab 20 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG002","title":"Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\< 35 kg were administered durvalumab 30 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG003","title":"Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the CSP for whom any post-dose data were available who did not violate or deviate from the CSP in ways that would significantly affect the PK analysis. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","timeFrame":"Pre-infusion and post-infusion on Cycle 2 Day 1, and Cycle 2 Day 8","title":"Dose-Finding Phase: (AUC 0-14) of Tremelimumab","type":"PRIMARY","unitOfMeasure":"day*mcg/mL"}